Clinical Trials for Cancer Treatment

Study Title:

BGB-3111-308 A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

What is the purpose of the study? (in Layman's terms, please describe the study)

The purpose of this study is to find out if the investigational drug called zanubrutinib (BGB-3111 or Brukinsa) when given together with obinutuzumab for follicular lymphoma (FL) or given together with rituximab for marginal zone lymphoma (MZL) can help control the disease and increase the length of your complete remission or partial remission compared to a commonly used treatment combination: lenalidomide plus rituximab treatment. The study will not only compare efficacy, but also safety, tolerability, and your quality of life between the investigational treatment and the commonly used treatment.

Upstate Institutional Review Board (IRB) Number:

2122498

Study/Protocol ID:

BGB-3111-308

Study Phase:

Patient Age Group:

Adults

Principal Investigator:

Bernard J Poiesz, MD

What is involved if I participate?

How long is the study?
The estimated length of the study is approximately 8 years, but your time on the study might differ based on how you respond to the study drugs.
Is transportation provided or reimbursed?
Yes
Is parking provided or reimbursed?
Yes
What tests and procedures are involved?
Please contact CRA for more information.

Where will the study take place?

University Hospital-Downtown Campus
Some procedures are possible at Upstate Community Hospital
Consenting only at Upstate Cancer Center at Verona, Upstate Cancer Center at Oswego